Calcific uremic arteriolopathy: advances in pathogenesis and treatment
Related Experiment Video
Updated: Jul 16, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Natasha M Rogers1, David J O Teubner, P Toby H Coates
1Department of Nephrology and Transplantation Services, The Queen Elizabeth Hospital and Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Insights
Calcific uremic arteriolopathy (CUA) is a severe complication in dialysis patients. Research explores new causes and treatments like hyperbaric oxygen and sodium thiosulfate for this life-threatening condition.
Area of Science:
- Nephrology
- Vascular Biology
- Dermatology
Background:
- Calcific uremic arteriolopathy (CUA) is a rare, life-threatening complication of chronic renal failure (CRF).
- It presents as painful, nonhealing skin lesions (eschars) with panniculitis and dermal necrosis, increasingly recognized in dialysis patients.
- Pathognomonic findings include vascular calcification, intimal arterial hypertrophy, and small vessel thrombosis.
Purpose of the Study:
- To review the current understanding of calcific uremic arteriolopathy (CUA) pathophysiology.
- To discuss emerging etiological factors and novel therapeutic strategies for CUA management.
Main Methods:
- Literature review of calcific uremic arteriolopathy (CUA) cases and research.
- Analysis of clinical features, pathological findings, and treatment outcomes.
Main Results:
- Consistent clinical features include hyperparathyroidism and elevated serum phosphate.
- Potential new etiological factors identified: reduced serum fetuin-A and smooth muscle cell abnormalities in uremia.
- Promising treatments reported in case series: hyperbaric oxygen, sodium thiosulfate, biphosphonates, and tissue plasminogen activator.
Conclusions:
- Understanding CUA mechanisms and exploring new treatments offer hope for managing this severe condition.
- The role of parathyroidectomy in CUA outcomes remains under investigation.
- New therapeutic approaches show promise for improving diagnosis and management of CUA.
Abstract:
Calcific uremic arteriolopathy (CUA) is a rare but serious life-threatening complication of CRF that manifests as painful nonhealing eschars in association with panniculitis and dermal necrosis. This condition is being increasingly recognized and reported as a contributing factor to death in dialysis patients. The pathognomic lesion is vascular calcification with intimal arterial hypertrophy and superimposed small vessel thrombosis. Hyperparathyroidism and elevated concentrations of serum phosphate remain consistent clinical features of most cases reported. Controversy still exists regarding the role of parathyroidectomy in this condition with some studies suggesting improved outcome with surgical intervention. A number of potential new etiological factors have been identified including reduced serum levels of a calcification inhibitory protein alpha,2-Heremans-Schmid glycoprotein (Fetuin-A) and abnormalities in smooth muscle cell biology in uremia. Promising new treatment options including hyperbaric oxygen therapy and sodium thiosulfate infusion have been reported in case series. Benefits from biphosphonates and tissue plasminogen activator have also been reported. Overall these new treatment approaches and understanding of potential mechanisms underlying this important severe clinical condition offer new hope in the diagnosis and management of this severely morbid and often fatal condition.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care

